Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups.
Bastos-Oreiro M, Gutierrez A, Reguera JL, Iacoboni G, López-Corral L, Terol MJ, Ortíz-Maldonado V, Sanz J, Guerra-Dominguez L, Bailen R, Mussetti A, Abrisqueta P, Hernani R, Luzardo H, Sancho JM, Delgado-Serrano J, Salar A, Grande C, Bento L, González de Villambrosía S, García-Belmonte D, Sureda A, Pérez-Martínez A, Barba P, Kwon M, Martín García-Sancho A. Bastos-Oreiro M, et al. Among authors: salar a. Front Immunol. 2022 Jul 12;13:855730. doi: 10.3389/fimmu.2022.855730. eCollection 2022. Front Immunol. 2022. PMID: 35911769 Free PMC article.
R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group). Martín A, et al. Among authors: salar a. Haematologica. 2008 Dec;93(12):1829-36. doi: 10.3324/haematol.13440. Epub 2008 Oct 22. Haematologica. 2008. PMID: 18945747 Free article.
Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era.
Sancho JM, Orfao A, Quijano S, García O, Panizo C, Pérez-Ceballos E, Deben G, Salar A, González-Barca E, Alonso N, García-Vela JA, Capote J, Peñalver FJ, Provencio M, Arias J, Plaza J, Caballero D, Morado M, Feliu E, Ribera JM; Spanish Group for the Study of CNS Disease in NHL. Sancho JM, et al. Among authors: salar a. Eur J Haematol. 2010 Oct;85(4):321-8. doi: 10.1111/j.1600-0609.2010.01478.x. Epub 2010 Jul 28. Eur J Haematol. 2010. PMID: 20528905
Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
Sanchez-Gonzalez B, Peñalver FJ, Medina A, Guillén H, Calleja M, Gironella M, Arranz R, Sebastian E, de Oña R, Cánovas A, de la Fuente I, Grande C, Sancho JM, Perez R, Domingo E, Lopez-Lorenzo JL, Prieto E, Panizo C, Gorosquieta A, Perez I, Cervera JM, Marin M, Mencha C, Ramila E, Salar A. Sanchez-Gonzalez B, et al. Among authors: salar a. Leuk Res. 2012 Jun;36(6):709-14. doi: 10.1016/j.leukres.2011.10.024. Epub 2011 Dec 7. Leuk Res. 2012. PMID: 22154023
Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
Redondo AM, Pomares H, Vidal MJ, Pascual MJ, Quereda B, Sancho JM, Polo M, López J, Conde E, Jarque I, Alonso N, Ramírez MJ, Fernández P, Sayas MJ, Requena MJ, Salar A, González JD, González-Barca E, Arranz R, Caballero D, Martín A. Redondo AM, et al. Among authors: salar a. Br J Haematol. 2014 Mar;164(5):668-74. doi: 10.1111/bjh.12676. Epub 2013 Nov 26. Br J Haematol. 2014. PMID: 24274082 Free article.
Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome.
Muñiz C, Martín-Martín L, López A, Sánchez-González B, Salar A, Almeida J, Sancho JM, Ribera JM, Heras C, Peñalver FJ, Gómez M, González-Barca E, Alonso N, Navarro B, Olave T, Sala F, Conde E, Márquez JA, Cabezudo E, Cladera A, García-Malo M, Caballero MD, Orfao A; Spanish Group for the Study of Central Nervous System Disease in Non-Hodgkin Lymphoma. Muñiz C, et al. Among authors: salar a. Blood. 2014 Mar 20;123(12):1864-9. doi: 10.1182/blood-2013-11-537993. Epub 2014 Feb 5. Blood. 2014. PMID: 24501214 Free article.
[Central nervous system relapse in diffuse large B cell lymphoma: Risk factors].
Sancho JM, Ribera JM; Working Group on Diagnosis, Prevention and Treatment of CNS Infiltration in Patients with DLBCL. Sancho JM, et al. Med Clin (Barc). 2016 Jan 15;146(2):74-80. doi: 10.1016/j.medcli.2014.12.025. Epub 2015 Mar 24. Med Clin (Barc). 2016. PMID: 25817451 Review. Spanish.
Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14.
Gutiérrez A, Bento L, Bautista-Gili AM, Garcia F, Martinez-Serra J, Sanchez B, Martorell C, Gines J, Garcia L, Gimeno E, Ferraro M, Del Campo R, Bargay J, Perez A, Vercher J, Scaff M, Pacheco A, Ballester C, Garcia F, Ramos R, Salar A, Besalduch J. Gutiérrez A, et al. Among authors: salar a. PLoS One. 2015 Apr 24;10(4):e0123978. doi: 10.1371/journal.pone.0123978. eCollection 2015. PLoS One. 2015. PMID: 25909361 Free PMC article.
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
Martín A, Redondo AM, Dlouhy I, Salar A, González-Barca E, Canales M, Montes-Moreno S, Ocio EM, López-Guillermo A, Caballero D; Spanish Group for Lymphomas and Autologous Bone Marrow (GELTAMO). Martín A, et al. Among authors: salar a. Br J Haematol. 2016 Apr;173(2):245-52. doi: 10.1111/bjh.13945. Epub 2016 Feb 5. Br J Haematol. 2016. PMID: 26847165 Free article. Clinical Trial.
Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.
González-Barca E, Canales M, Salar A, Ferreiro-Martínez JJ, Ferrer-Bordes S, García-Marco JA, Sánchez-Blanco JJ, García-Frade J, Peñalver J, Bello-López JL, Sancho JM, Caballero D; GELTAMO group. González-Barca E, et al. Among authors: salar a. Ann Hematol. 2016 May;95(6):893-9. doi: 10.1007/s00277-016-2648-4. Epub 2016 Mar 30. Ann Hematol. 2016. PMID: 27025508 Free PMC article.
190 results